Katherine Tuttle, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to unpack new FIND-CKD finerenone analyses from ASN 2026.
News|Articles|October 2, 2026
5 Psychiatry Headlines You Missed in September 2026
Author(s)Chelsie Derman
Fact checked by: Tim Smith
Here, we review the top psychiatry news in September 2026, from DT120's second Breakthrough Therapy designation to the FDA psychedelic hearing.
Advertisement
Advertisement
September brought regulatory and research momentum for psychedelic therapies in psychiatry. The US Food & Drug Administration (FDA) granted DT120 (lysergide) orally disintegrating tablet (ODT) a second Breakthrough Therapy designation, this time in
Related to this article
Jicheng Lv, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to discuss 2-year TELIGAN data for telitacicept in IgAN.
A PROTECT biomarker analysis shows sparsentan reduced urinary sCD163, BAFF, C5b-9, and IL-6 vs irbesartan through 110 weeks in IgA nephropathy.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, review early MiniMed Vivera data on optional meal announcements and twiist's new type 2 diabetes clearance.
Real-world data in 1477 patients on dialysis show tenapanor reduced serum phosphate at 6 months with or without background phosphate binders.
Approval rests on the phase 3 AFFIRM trial, in which 56% of patients reached clinical remission at week 12 vs 30% with placebo.
Jean Elwing, MD, discusses what drove ralinepag's reduction in PAH clinical worsening in ADVANCE Outcomes and where the it could fit if approved.
Jean Elwing, MD, discusses a CHEST 2026 subgroup analysis showing ralinepag reduces clinical worsening in PAH even among patients with low-risk criteria.
Advertisement
Advertisement